NCT01718743 · OUTCOME

Treatment-related Unmanageable Toxicities, Including Grade 3 Non-hematologic Effects, or Grade 4 Hematologic Effects

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: throughout study treatment and up to 30 days after completion of study treatment, up to 119 months

What was measured

Toxicity data will be summarized by frequency tables.

Groups in this outcome

Treatment (Ixazomib Citrate, Lenalidomide)

Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Ixazomib Citrate, Lenalidomide)	64

Reported measurements

Serious AE-Lung Infections

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Ixazomib Citrate, Lenalidomide)	12	Not reported	Not reported	Not reported	Not reported

Serious AE-Treatment-related secondary malignancy

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Ixazomib Citrate, Lenalidomide)	9	Not reported	Not reported	Not reported	Not reported

Serious AE-Respiratory Disorders including respiratory failures

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Ixazomib Citrate, Lenalidomide)	8	Not reported	Not reported	Not reported	Not reported

Serious AE-other infections

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Ixazomib Citrate, Lenalidomide)	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
12
title
Serious AE-Lung Infections
categories
measurements
group Id
OG000
value
9
title
Serious AE-Treatment-related secondary malignancy
categories
measurements
group Id
OG000
value
8
title
Serious AE-Respiratory Disorders including respiratory failures
categories
measurements
group Id
OG000
value
5
title
Serious AE-other infections

denoms

counts
group Id
OG000
value
64
units
Participants

description

Toxicity data will be summarized by frequency tables.

groups

description
Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
id
OG000
title
Treatment (Ixazomib Citrate, Lenalidomide)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

throughout study treatment and up to 30 days after completion of study treatment, up to 119 months

title

Treatment-related Unmanageable Toxicities, Including Grade 3 Non-hematologic Effects, or Grade 4 Hematologic Effects

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice